Xcout Intel
Sparrow Pharmaceuticals
Sparrow Pharmaceuticals, Inc. is a Boston-based biopharmaceutical company focused on developing targeted cardiometabolic therapeutics. The company aims to address conditions such as diabetes and endocrine diseases with precision therapies.
Subscribe to see Sparrow Pharmaceuticals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Sparrow Pharmaceuticals at a glance
Sparrow Pharmaceuticals is a pharmaceuticals company headquartered in United States. Its most recent funding round, Series A, raised $95M in September 2025. Xcout tracks 16 named people at Sparrow Pharmaceuticals, including Robert Jacks (President & Chief Executive Officer).
Sparrow Pharmaceuticals leadership
- Robert JacksPresident & Chief Executive Officer
- George EldridgeChief Financial Officer
- Dr. David KatzChief Scientific Officer
- FRANK CZERWIECChief Medical Officer
- Dora FerrariSenior Vice President, Development Operations
- Jamie MacPhersonSenior Vice President, Regulatory Affairs & Quality Assurance
10 more named people on record for Sparrow Pharmaceuticals, with roles, board committees and tenure — see the full roster →
Sparrow Pharmaceuticals funding rounds
The 5 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $95M | 3 named | |
| SEC Form D filing | $61.8M | — | |
| SEC Form D filing | $10M | — | |
| Series U | $10M | 3 named | |
| — | $50M | 6 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Sparrow Pharmaceuticals competitors
A few of Sparrow Pharmaceuticals's closest competitors — see the full list of competitors and alternatives →
Arisaph Pharmaceuticals Inc. is a Boston, Massachusetts-based biopharmaceutical company that utilizes drug discovery platforms to develop novel therapies for cancer, cardiovascular disease, and diabetes. The company's pipeline includes small molecule inhibitors and differentiated medicines aimed at cardiometabolic diseases and oncology.
Boston Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company that acquires, develops, and advances drug candidates for serious diseases. It works with pharmaceutical and biotechnology partners to bring clinical-stage medicines toward commercialization and serves patients with significant unmet medical needs.
Yarrow Bioscience is a U.S.-based biotechnology company focused on the development of treatments for autoimmune diseases. The company has been involved in significant pharmaceutical deals, including the acquisition of drug candidates for thyroid conditions.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of treatments within cellular metabolism and associated biological domains. Its lead product, PYRUKYND (mitapivat), serves as an activator for both healthy and various mutated forms of the pyruvate kinase (PK) enzyme, targeting the management of hemolytic anemias. Additionally, AG-946, an investigational compound, is currently undergoing Phase I clinical evaluation for hemolytic anemias and other conditions. Established in 2007, Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
SCOHIA PHARMA, Inc. is a clinical-stage specialty bioventure headquartered in Fujisawa, Japan. Established in 2017, the company focuses its research and development on lifestyle-related diseases including cardiovascular, metabolic, and renal disorders.
Get Sparrow Pharmaceuticals's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Sparrow Pharmaceuticals in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 6 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access